Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial to evaluate the safety and efficacy of OPB-101 in platinum-resistant ovarian cancer is ongoing. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• OPB-101

Snippet

Sponsor: Outpace Bio, Inc. | Conditions: Ovarian Cancer Recurrent, Ovarian Cancer | Phase 1 | Status: RECRUITING